These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside AheadThe Motley Fool • 07/24/26
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026Business Wire • 07/22/26
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 07/16/26
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?Zacks Investment Research • 07/09/26
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal CancerBusiness Wire • 06/22/26
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/04/26
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/03/26
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026Business Wire • 05/30/26
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket24/7 Wall Street • 05/28/26
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference TranscriptSeeking Alpha • 05/28/26
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in JuneBusiness Wire • 05/27/26
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training InitiativeBusiness Wire • 05/27/26
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch NearMarketBeat • 05/23/26
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor TypesBusiness Wire • 05/21/26